Neuvonique Research Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 45.33%
- Ebitda 45.33%
- Total Assets %
About Neuvonique Research Remedies
Neuvonique Research Remedies Private Limited (NRRPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 September 2017 (Seven years and four months 18 days old ). Its registered office is in Panvel, Maharashtra.
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sachin Shanbhag and Prakash Parhad serve as directors at the Company.
Company Details
-
LocationPanvel, Maharashtra
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100MH2017PTC300017
-
Company No.
300017
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Sep 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Neuvonique Research Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin Shanbhag
|
Director | 22-Sep-2017 | Current |
|
Prakash Parhad
|
Director | 22-Sep-2017 | Current |
Financial Performance of Neuvonique Research Remedies.
Neuvonique Research Remedies Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 45.33% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neuvonique Research Remedies?
Unlock access to Neuvonique Research Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Eddies Innovative Research Center LlpPrakash Parhad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neuvonique Research Remedies?
Unlock and access historical data on people associated with Neuvonique Research Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuvonique Research Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuvonique Research Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.